Research
Yale University is recognized world-wide as a leader in basic, clinical, epidemiological and translational research. Yale is committed to the development of novel diagnostic and therapeutic treatment options as well as furthering the knowledge of basic biological, physiological and genetic processes. Below are examples of current and published research focused on increasing the knowledge of, as well as enhancing the care of, women who have high risk pregnancies and the baby who has been diagnosed with a fetal anomaly.
Multigate Doppler with Global Acquisition and Signal Processing
Multigate Doppler with Global Acquisition and Signal Processing
“Multigate Doppler with Global Acquisition and Signal Processing (G.A.S.P.) in the uteroplacental and fetal circulations.” This new non-invasive Doppler ultrasound technology is being applied to a variety of areas concerning women’s health, including early pregnancy assessment and gynecologic malignancy screening. This project is a collaboration between the Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Department of Obstetrics and Gynecology; University of Milan, Bicocca, Milan, Italy; Department of Engineering, University of Florence, Florence, Italy; Esaote, Florence, Italy.
Predicting Late and Early Perinatal Stroke
Predicting Late and Early Perinatal Stroke
“Predicting Late and Early Perinatal Stroke in High Risk Pregnancies And High Risk Neonates.” The goal is to identify a very high risk population for perinatal stroke suitable for prevention or early treatment.
Neural Stem Cells and Synthetic Preimplantation Factor
Neural Stem Cells and Synthetic Preimplantation Factor
“Neural Stem Cells and synthetic Preimplantation Factor (sPIF) to treat perinatal brain injury in the rodent.” Pre-Implantation-Factor (PIF) +/- neural stem cells will be investigated as a therapeutic option to treat perinatal brain injury.
More projects
- Antithrombin Levels Preceding Placenta Mediated Complications
“Antithrombin levels preceding placenta mediated complications.” The objective of this study is to determine antithrombin and Preimplantation Factor levels in pregnancy complications, prior to the onset of clinical disease.
- Preimplantation Factor (PIF)
“Preimplantation factor (PIF): a biomarker for viable embryo selection after in vitro fertilization and for pregnancy outcome.” This proposal is a multicenter study which investigates the potential role of Preimplantation Factor as a diagnostic test in two settings; namely, to predict IVF success when measured in embryo culture media, and to predict viable pregnancy and a range of placenta mediated complications.
- Safety and Efficacy of Recombinant Antithrombin in Pre-term Pre-eclampsia
Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Pre-term Pre-eclampsia (PRESERVE-1): RB AT PPE-01-13. Funding Agency: rEVO Biologics (formerly GTC Biotherapeutics). This is a multicenter, randomized, placebo controlled trial to determine whether maternal administration of recombinant antithrombin will prolong gestational age in the setting of preeclampsia at 24 to less than 28 wks.
- Fetal Chromosome Abnormalities
“Non-invasive determination of fetal chromosome abnormalities” This multicenter study is aimed to determine whether isolating fetal cells using antibody-directed fetal nucleated red blood cells can be investigated by a number of standard molecular tests including fluorescent in situ hybridization (FISH).